LiGHT 2026

Strados Labs Forms Collaboration with Boehringer Ingelheim for its IPF Pilot Study

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

WebMD Ignite Ruby Transforms Healthcare Marketing...

WebMD Ignite has announced the launch of WebMD Ignite...

Mayo Clinic Study Validates AI Tool...

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI...

The United Kingdomโ€™s Medicines and Healthcare products Regulatory Agency...

Strados Labs announced a collaboration with Boehringer Ingelheim to remotely monitor patients using its FDA-cleared pulmonary wearable device in an upcoming idiopathic pulmonary fibrosis (IPF) pilot study. In Boehringer Ingelheimโ€™s pilot study, the Strados RESP Biosensor will be used to monitor cough and crackles in IPF patients at home aiming to accelerate the development of much needed new therapies for people living with IPF.

Research has suggested that cough may be associated with worse outcomes in pulmonary fibrosis. Boehringer Ingelheim will assess how monitoring cough and crackles with the RESP Biosensor can be used to monitor the status of patients with this disease, with the aim of advancing clinical research and the development of next therapies to transform the lives of people with pulmonary fibrosis.

โ€œCurrently, disease progression in IPF is measured by a decline in forced vital capacity (FVC).โ€ Says Strados Labs CEO & Cofounder Nick Delmonico. โ€œWe are thrilled to help Boehringer Ingelheim explore cough and crackles as an additional method to monitor disease while allowing patients to stay in the comfort of their homes.โ€

The RESP Biosensor is a lightweight, non-invasive wearable device that is used in clinical trials to monitor cough frequency, severity, and type along with wheezing and other abnormal sounds. The device is also used for remote monitoring in healthcare to address the problem of patient readmissions associated with COPD, asthma, and other cardiopulmonary diseases.

 

 

Never miss a healthcare headline

Healthcare moves fast โ€“ stay on top of it with our must - read briefings.

  • The top hospital and healthcare stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments transforming global healthcare management

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media PackNow

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Latest stories

Related stories

Mayo Clinic Study Validates AI Tool DEXI for Skin Lesion Assessment

Researchers at Mayo Clinic have found that an artificial...

MHRA Outlines New Agenda for AI Medical Devices at AdvaMed

The United Kingdomโ€™s Medicines and Healthcare products Regulatory Agency...

UK Confirms Indefinite Use of CE Marked Medical Devices

The United Kingdom government has officially confirmed the indefinite...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป